Neutrogena faces boycott calls after Hayden Panettiere's death revives postpartum depression claim

Neutrogena is facing mounting calls for a boycott following the death of Hayden Panettiere, the actor best known for Heroes and Nashville, who died at her apartment in Greenville, South Carolina, on 16 August at the age of 36. An autopsy found no signs of trauma and no indication of foul play; the cause of her death remains under investigation.

The backlash centres not on how she died but on what she said while she was alive. In her memoir This Is Me: A Reckoning, published earlier this year, Panettiere alleged that the skincare brand — her commercial partner for a decade — moved to end their relationship after she spoke publicly about her postpartum depression in 2015.

At a glance

• Hayden Panettiere died at her apartment in Greenville, South Carolina, aged 36; she would have turned 37 within the week
• An autopsy found no signs of trauma or foul play; the cause of death remains under investigation
• In her 2026 memoir This Is Me: A Reckoning, she alleged Neutrogena moved to drop her after she discussed postpartum depression in 2015
• Her endorsement deal with the brand ran from 2005 to 2015
• Neutrogena, owned by Kenvue, had not responded to requests for comment as of Wednesday
• Boycott calls have spread across social media since her death

The allegation at the heart of it

Panettiere's endorsement deal with Neutrogena ran from 2005 to 2015, making her one of the brand's most recognisable faces for a generation of consumers. In the memoir, and in interviews promoting it in May — including Jay Shetty's On Purpose podcast — she said the company wanted to "fire" her after she discussed her postpartum depression diagnosis on Live with Kelly and Michael in 2015.

Her account was that speaking about the condition was treated as a violation of the deal's morals clause — a claim that, when she made it in May, drew criticism of the brand but no formal response. Neutrogena has never publicly detailed why the partnership ended.

How a memoir claim became a boycott

Her death transformed the story. Within days, the allegation resurfaced across social media, and criticism of the brand hardened into organised calls to stop buying its products. The pattern is familiar in consumer activism: a grievance that simmered for months found a catalyst, and the brand's silence — defensible in May — began to read as indifference.

Neutrogena, which is owned by the consumer health company Kenvue, has not commented. NBC News reported that it had approached the company on Wednesday and received no response.

The crisis-management view

Public relations specialists see the company's position as increasingly untenable. Molly McPherson, a crisis management expert, said of the brand's approach: "Now what they need to see is action. This is not a time for a press release." She added that "the silence is deafening here."

The dilemma is real. Any statement invites scrutiny of a contractual decision made a decade ago, and of how a global brand handled a spokeswoman's mental health disclosure. Saying nothing, though, cedes the narrative entirely to the boycott.

Why the postpartum claim resonates

Panettiere was among the first high-profile American actors to speak openly about postpartum depression, at a time when the condition carried far more stigma than it does now. Her disclosure in 2015 was widely credited with prompting other women to seek help — which is precisely why the claim that it cost her a contract has provoked such anger.

The reaction since her death reflects that history. For many of those calling for a boycott, the issue is not one actor's endorsement deal but what the alleged decision said about how corporations treated women's mental health.

What happens next

The investigation into Panettiere's death continues, with toxicology results expected to take weeks. Neutrogena's response — or continued silence — will determine how long the consumer pressure lasts; boycott movements typically fade without fresh developments, but a confirmed cause of death or a statement from her family could renew attention.

Kenvue, which faces the reputational exposure at group level, has likewise said nothing publicly. As of this week, the company's approach appears to be to wait the story out.